PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2025

  • January 2017 •
  • 345 pages •
  • Report ID: 4826795 •
  • Format: PDF
PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2025

Summary
Ulcerative Colitis (UC) is a type of chronic IBD that causes inflammation and ulcers in the innermost lining of the colon and rectum. As a result, the colon’s ability to absorb water is decreased, which leads to progressive loosening of the stool, bloody stool, and sometimes cramping or abdominal pain, with urgency for bowel movement. Other associated symptoms of UC include loss of appetite, weight loss, fatigue, and anaemia in cases of severe bleeding.

It is estimated that the 2015 Ulcerative Colitis (UC) drug sales to be $5.64B across the seven major pharmaceutical markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan) covered in this report. By the end of the forecast period in 2025, sales will increase to over $6.58B at a Compound Annual Growth Rate (CAGR) of 1.6%, which is driven by approval/launch of nine pipeline therapies and anti-tumor necrosis factor (TNF) biosimilars.

In general, companies that are striving to enter the UC market are targeting all mild, moderate and severe UC patients. However, majority of late pipeline products are targeting UC patients refractory to steroids and anti-TNF therapies as well as anti-TNF naïve patients, as this population remains the most underserved group, with limited therapeutic options and high clinical unmet need.

Johnson & Johnson’s (J&J’s) Remicade was market leader in 2015 with $1.4B in sales for UC. However, the brand will be experiencing significant erosion from biosimilars across 7MM throughout the 10 year forecast period. To mitigate brand erosion in France, J&J has reduced Remicade price in the country and is available at a same price as its biosimilars, leaving the market more competitive.

The report “PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2025” provides an overview of UC, including epidemiology, aetiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

In particular, it provides the following -
- Annualized UC therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
- Provides strategic competitor assessment, market characterization, unmet needs, and implications for the UC therapeutics market.
- Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global UC therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Companies mentioned this report: Johnson & Johnson, AbbVie, Takeda Pharmaceuticals, Salix Pharmaceuticals, Pfizer, Roche, InDeX Pharmaceuticals, Lipid Therapeutics, Celgene, EA Pharma, Ferring, Tillotts Pharma

Scope
- Overview of UC, including epidemiology, aetiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized UC therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the UC therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global UC therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global UC therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global UC therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global UC therapeutics market from 2015-2025.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Loading...

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.